Advanced Mental Health Care, Juno Beach, Florida, USA
20 February 2014
Since the parietal cortex of MCI patient’s exhibits neurodegeneration and reduced activity, the current study will explore the potential beneficial effects of excitatory (10 Hz) parietal Brainsway® Deep TMS on the symptoms of MCI. The trial schedule for each subject will include 8 weeks of tri-weekly treatment. Additionally, an evaluation will be conducted one year after the end of treatment.
The rationale for the choice of these stimulation parameters is based on previous studies utilizing Deep TMS for the treatment of major depression, which demonstrated the efficacy (as measured by depression and cognitive scales) of high-frequency stimulation applied over the prefrontal cortex. Further justification for this choice was obtained from the results of the second safety study conducted with the H-coils and the results of the depression clinical trials at the Shalvata Hospital (without drug therapy) and at the Hadassah Ein Kerem Hospital (in conjunction with drug therapy).
Furthermore, TMS studies performed with Alzheimer’s patients indicate a greater sensitivity of these patients to stimulation. This finding was taken into consideration when selecting the stimulation parameters for the current study’s protocol, even though the current study involves MCI patients rather than AD patients.
Contact: Aron Tendler, MD tel:561-333-8884 email: email@example.com
Principal Investigator: Aron Tendler, MD